ORACLE: Observation of ResiduAl Cancer with Liquid biopsy Evaluation (CTMS# 22-0052)
This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment
This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment
Physical Effects of Cancer
Genitourinary (GU) Cancer Program
Cancer Prevention and Screenings
Cancer Genetics Program
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
Cancer Treatments
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)